Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Oxurion NV to Provide Business and Clinical Update at Upcoming American Academy of Ophthalmology annual meeting (AAO) and Ophthalmology Innovation Summit (OIS @AAO) in San Francisco

Poster Presentation Featuring Positive Topline data from Phase 1 Trial Evaluating THR-149, a novel, potent plasma kallikrein inhibitor for DME
9 Oct 2019

Leuven, Belgium , 9 October 2019 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, today announces that the Company will be providing a business and clinical update at upcoming American Academy of Ophthalmology's annual meeting (AAO) and Ophthalmology Innovation Summit (OIS@AAO) in San Francisco.

Patrik De Haes, MD, CEO of Oxurion will be presenting the Company’s business and diabetic eye disease clinical pipeline at the Ophthalmology Innovation Summit (OIS) meeting which will be held on 10th October 2019, at the Hilton San Francisco Union Square. In his presentation, Dr De Haes will focus on the prospects for Oxurion’s two VEGFindependent drug candidates, THR-149 and THR-687, which are being developed for diabetic macular edema (DME). THR-149 has recently completed a positive Phase 1 study and Oxurion expects to announce results from an on-going Phase 1 study with THR-687, a panRGD integrin antagonist, towards the end of 2019.

At the American Academy of Ophthalmology's annual meeting (AAO), Arshad M Khanani, MD will present ‘A Phase 1, Open Label, Dose Escalation study of THR-149 for the Treatment of Diabetic Macular Edema (DME)’ (poster presentation – P0455).

Topline data from the Phase 1 study (n=12) evaluating THR-149 for treatment of DME show that THR-149 is well-tolerated and safe. Study data also indicate that a single injection of THR-149 resulted in an immediate (day 1) positive impact on patient’s Best Corrected Visual Acuity (BCVA). This improvement continued with an average improvement in BCVA of up to 7.5 letters being achieved at Day 14. Importantly, this activity was also maintained with an average improvement in BCVA of 6.4 letters at the end of study (Day 90).

THR-149 has been developed with Bicycle Therapeutics (Nasdaq: BCYC). Oxurion holds the exclusive license to the PKal inhibitor portfolio originating from this partnership.